Shanghai standardizes and adjusts dental medical service pricing items; TOPCHOICE MEDICAL CORPORATION, WHOLE SHINE MEDICAL, Zhenghai Bio-tech and others release latest financial reports; a clinic pai…

Shanghai standardizes and adjusts dental medical service pricing items, effective November 20

On October 28, 2026, the Shanghai Municipal Healthcare Security Administration published a notice on "dental medical service pricing items," specifying that the new pricing standards will take effect from November 20, 2026. Tooth extraction fee is 48 yuan/tooth (tertiary) and 42 yuan/tooth (secondary, primary), impacted tooth extraction fee is 320 yuan/tooth (tertiary) and 279 yuan/tooth (secondary, primary), with a 25% reduction if no flap elevation is required. Class A items are covered by basic medical insurance, while Class B items require insured individuals to pay out of pocket. Non-disease treatment items such as orthodontics and dental restoration are not covered by medical insurance.

NMPA releases new inspection guidelines for custom-made dentures, effective November 1

On October 28, 2026, the National Medical Products Administration (NMPA) released the "Guidelines for Inspection of Custom-made Dentures," effective from November 1, 2026, listing a total of 190 inspection items, of which 38 are key items. The guidelines incorporate custom-made dentures into the scope of production license verification and post-market supervision and inspection, requiring that procurement, incoming goods acceptance, testing, and production management comply with the newly revised "Medical Device Production Quality Management Practices." The original "Guidelines for On-site Inspection of Custom-made Dentures under the Medical Device Production Quality Management Practices" (Shi Yao Jian Xie Jian [2016] No. 165) is simultaneously abolished.

Inner Mongolia Autonomous Region comprehensively promotes the implementation and application of Unique Device Identification (UDI)

Recently, the Inner Mongolia Medical Products Administration, Health Commission, and Healthcare Security Administration jointly issued a "Plan," specifying that from June 1, 2027, all Class II medical devices, and from June 1, 2029, all Class I medical devices must be assigned a Unique Device Identification (UDI), and requiring that production, filing, distribution, and use segments upload UDI data before market launch and maintain consistency with medical insurance classification. The plan also requires relevant departments to strengthen regulatory information sharing and promote UDI application across the entire chain of pharmaceuticals, medical care, and medical insurance.

TOPCHOICE MEDICAL CORPORATION 2026Q3: Operating revenue 915 million yuan, up 2.93% year-on-year; investment income up about 3.3 times in first three quarters

On October 27, 2026, TOPCHOICE MEDICAL CORPORATION released its unaudited 2026 third-quarter report, with single-quarter operating revenue of 915 million yuan, up 2.93% year-on-year; net profit attributable to shareholders of the parent company of 212 million yuan, up 3.21% year-on-year. Cumulative investment income for the first three quarters was 128 million yuan, up 332.24% year-on-year. The board of directors approved a profit distribution plan of a cash dividend of 4.5 yuan per 10 shares (tax inclusive), totaling approximately 200 million yuan, accounting for 29.85% of the net profit attributable to shareholders of the parent company for the first three quarters, subject to submission to the shareholders' meeting for deliberation. As of September 30, short-term borrowings were 450 million yuan. The 2,833,164 repurchased shares completed cancellation registration on September 2, 2026, with total share capital changing from 447,289,117 shares to 444,455,953 shares.

WHOLE SHINE MEDICAL 2026Q3: Revenue 206 million yuan, down 3.23% year-on-year; net profit attributable to shareholders of the parent company turned from loss to profit year-on-year

On October 30, 2026, WHOLE SHINE MEDICAL disclosed its 2026 Q3 report, with single-quarter revenue of 206 million yuan, down 3.23% year-on-year, and net profit attributable to shareholders of the parent company of 1.7893 million yuan, achieving a year-on-year turnaround from loss to profit; cumulative revenue for the first three quarters was 520 million yuan, down 1.23% year-on-year, with cumulative net loss attributable to shareholders of the parent company of 12.2366 million yuan, a year-on-year loss reduction of 53.67%. In terms of costs and expenses, operating cost was 241 million yuan, down 12.54%, and R&D expenses were 9.2361 million yuan, down 20.70%. Operating Cash Flow was 45.5987 million yuan, turning from negative to positive. In addition, one director resigned from the fifth board of directors due to personal reasons.

HILE 2026Q3: Single-quarter revenue 103 million yuan, up 158.09% year-on-year; oral business revenue and profit both increased

On October 30, 2026, SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. released its 2026 third-quarter report, with single-quarter operating revenue of 103 million yuan, up 158.09% year-on-year, net profit attributable to shareholders of the parent company of 10.3014 million yuan, an increase of 391.75%, and goodwill reaching 564 million yuan. As of September 30, cash and cash equivalents were 124 million yuan, total liabilities were 363 million yuan, and net cash flow from financing activities was 26.3733 million yuan, including 85.00 million yuan in cash received from borrowings.

Zhenghai Bio 2026Q3: Revenue 71.3918 million yuan, down 18.76% year-on-year; net profit attributable to shareholders of the parent company down 27.67% year-on-year

On October 26, 2026, Zhenghai Bio released its 2026 third-quarter report, with single-quarter operating revenue of 71.3918 million yuan, down 18.76% year-on-year; net profit attributable to shareholders of the parent company of 15.1281 million yuan, down 27.67% year-on-year. Cumulative operating revenue for the first three quarters was 231 million yuan, and net profit attributable to shareholders of the parent company was 48.4342 million yuan, down 27.80% year-on-year; net profit attributable to shareholders excluding non-recurring gains and losses was 40.0012 million yuan, down 32.04% year-on-year. As of September 30, inventory was 39.3769 million yuan.

Perfect 2026Q3: Revenue 488 million yuan, up 21.44% year-on-year; net profit attributable to shareholders of the parent company down 17.39% year-on-year

On October 28, 2026, Perfect disclosed its 2026 third-quarter report, with single-quarter operating revenue of 488 million yuan, up 21.44% year-on-year; net profit attributable to shareholders of the listed company of 27.7129 million yuan, down 17.39% year-on-year; net profit excluding non-recurring gains and losses of 27.9936 million yuan, down 12.77% year-on-year. As of September 30, 2026, the company's total assets were 2.442 billion yuan, and owners' equity attributable to shareholders of the listed company was 1.134 billion yuan.

LMZ 2026 Q3: Revenue 238 million yuan, down 18.76% year-on-year

On October 29, Liuzhou LMZ Co., Ltd. released its unaudited 2026 third-quarter report, with operating revenue of 712 million yuan for the first three quarters, down 12.65% year-on-year, and net loss attributable to shareholders of the parent company of 31.9086 million yuan; single-quarter operating revenue was 238 million yuan, down 18.76% year-on-year, with a net loss of 27.2274 million yuan, fair value change loss of -28.6780 million yuan, and net Operating Cash Flow of -10.4794 million yuan. On August 3, the company completed the transfer of 154,000,000 shares (28% of total share capital) at a transaction price of approximately 1.228 billion yuan, with the ultimate controller changing to the State-owned Assets Supervision and Administration Commission of Guangxi Zhuang Autonomous Region. Cash and cash equivalents decreased by 47.7467 million yuan net in the first three quarters, with an ending balance of 1.245 billion yuan.

National Bureau of Statistics: Profit of dental equipment manufacturing industry grew 59.6% in first three quarters of 2026

On October 27, 2026, the National Bureau of Statistics released industrial enterprise profit data for January-September 2026, showing that the profit of the manufacture of dental equipment and instruments industry grew 59.6% year-on-year, far higher than the 15.5% for industrial enterprises above designated size and 52.0% for high-tech manufacturing. The industry's growth rate was 44.1 percentage points higher than the overall rate and 7.6 percentage points higher than high-tech manufacturing. During the same period, the cost per 100 yuan of operating revenue for industrial enterprises above designated size was 85.02 yuan, down 0.45 yuan year-on-year, and the operating revenue profit margin was 5.68%, up 0.44 percentage points year-on-year.

Over 39,000 Australians apply for early withdrawal of retirement funds to pay for dental treatment, up 5.9% year-on-year

On October 22, 2026, the Australian Taxation Office (ATO) released dental compassionate release data for the 2025-26 fiscal year, with 39,010 people submitting applications and approved amounts reaching AUD 892 million (approximately RMB 4.198 billion), up about 9.1% year-on-year. Since July 1, 2025, the ATO has conducted more than 160 reviews and audits, with cumulative penalties exceeding AUD 1.5 million. The ATO reminds that early withdrawal of retirement funds may have tax implications.

Clinic pays 5,056 yuan in unbooked referral kickbacks, fined 200,000 yuan

Recently, the Juye County Market Supervision Administration imposed a fine of 200,000 yuan on a dental clinic. The penalty decision shows that the clinic's marketing manager promised a 8% kickback and paid a total of 5,056 yuan to two front desk staff of another clinic, with the payment not recorded in the company's accounting books, involving 4 patients in total; no illegal gains were confiscated, and no suspension or revocation of licenses was involved.

Facial AI vision company enters strategic cooperation with dental patient conversion platform, focusing on AI smile simulation technology

On October 22, 2026, facial AI company Banuba and dental patient conversion platform Your Social Smile (YSS) announced a strategic cooperation to launch real-time dental smile simulation technology based on AR and Generative AI. The technology allows patients to preview dental restoration results on any device within one minute and supports tracking of case acceptance. Banuba is an augmented reality technology company that has been operating in the market for more than 10 years, with business covering artificial intelligence, face tracking, virtual try-on, and virtual background technologies.

West China Hospital of Stomatology and other teams develop biomimetic nanoparticles, expected to combine antibacterial, anti-inflammatory, and periodontal tissue regeneration

On October 26, 2026, teams including West China Hospital of Stomatology published animal experiments in the International Journal of Oral Science, showing that the developed NMm@MINO biomimetic nanoparticle achieved in vitro bactericidal rates exceeding 99% against P. gingivalis and S. aureus, and significantly reduced inflammatory markers such as IL-6 and CRP in a rat Periodontitis Model, promoting alveolar bone recovery and soft tissue collagen remodeling. The study noted that clinical trials are still needed to verify its safety and efficacy in human periodontitis treatment.

New study: Music Therapy may reduce pain after wisdom tooth extraction

On October 13, 2026, a randomized double-blind clinical trial published by Universidade Christus in Brazil in the International Journal of Dentistry showed that patients undergoing Lower third molar extraction who listened to self-selected music during surgery had immediate postoperative pain VAS of 6.05±1.73, lower than the control group, and systolic blood pressure and respiratory rate were also lower than the control group. The time to first use of rescue analgesics in the music group was 104.00±24.63 hours, with 0.60±0.84 tablets, both significantly less than the control group (p<0.001 respectively), but no significant differences were observed between the two groups in Dental anxiety and postoperative quality of life. The study noted that Music Therapy may serve as an adjunctive non-pharmacological measure for Lower third molar extraction.

New study: AI 3D modeling of soft and hard tissues may improve consistency in simulated planning of Immediate implant placement in anterior teeth

On October 2, 2026, the Journal of Dentistry published online a proof-of-concept study showing that an AI-assisted 3D hybrid model of soft and hard tissues (PIM) in simulated planning of Immediate implant placement in anterior teeth for 30 maxillary anterior cases reduced the proportion of implants with inter-expert angular deviation exceeding 7° from 40% to 6.7%, with average inter-expert apical deviation reduced by 0.60 mm and average angular deviation reduced by 2.13°.

New study: Screen time exceeding 1 hour per day in early childhood associated with 27% higher odds ratio of Dental caries

On October 7, 2026, a retrospective cohort study of 71,438 children in Okinawa Prefecture, Japan, showed that children with average daily screen use exceeding 1 hour at age 3 had an adjusted odds ratio of 1.27 for Dental caries and an aOR of 1.55 for severe Dental caries, with the incident group accounting for only 2.7% of the sample. The study suggests a significant association between screen use and Dental caries risk, but the result is an association rather than causation.

New study: Patients with Periodontitis may have a higher risk of exudative retinal detachment

Recently, a population cohort study in Taiwan, China, found that between 2000 and 2020, patients with Periodontitis (167,530 each) had 437 cases (0.26%) of exudative retinal detachment (ERD), compared with 100 cases (0.06%) in the control group, with incidence rates of 16.74 and 3.55 per 10⁵ person-years, respectively, a crude risk ratio of 3.95, and adjusted risk ratios of 3.42 and 3.56. The study suggests a potential association between Periodontitis and ERD.